flanders.bio provides you with insights in the vibrant life sciences sector

Facts & Figures

CONSULT OUR LIFE SCIENCE DATABASE

 

Innovation is at the core of the life sciences sector and Belgium has a track record of developing ingenious ways to improve the quality of life of millions of people worldwide.

 

Not only extensive life sciences facilities support this high-level technology industry but also financial benefits for R&D companies, international collaborations that guarantee regular cash flow, world known educational systems, a promising product pipeline, and Belgium’s unique central location in Europe.

 

Belgium concentrates on a small territory (30,528 km2) more than 300 life sciences companies with biotech activities. In total, the life sciences sector employs more than 30,000 people (low bound estimation that does not take into account indirect employment generated by the sector). The majority of the companies is related to healthcare, but Belgium also has a strong representation of agricultural and industrial biotech companies.

 

The growing life sciences sector gathers 8 main Belgian universities, 19 research parks and 23 incubators, research institutes, academic hospitals, and clinical research organizations. Biotech companies have access to more than 500,000 square feet of highly flexible infrastructure.

 

Additional assets of Belgium includes: a supportive regulatory and political environment, a highly qualified and productive workforce, a competitive tax environment especially for research companies, a prominent location and an excellent logistical and business infrastructure.

News from flanders.bio and its members

argenx announces publication of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116 for the treatment of dyslipidemia

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced the publication in Nature Medicine of preclinical data on ARGX-116 inhibiting ApoC3, a metabolic target correlated with blood lipid levels, that provide further rationale for the therapeutic potential of anti-ApoC3 SIMPLE AntibodyTM ARGX-116 for the treatment of dyslipidemia.

Publication | 23 August 17
Read more
21
Aug
2017

Mithra Announces First Subject Completes Estelle® Phase III Study

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that the first European study subject has successfully completed 13 cycles of Estelle® and the end of study physician visit in the E4 Freedom Phase III study program. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP), and is currently being tested in two Phase III trials in Europe/Russia and in the US/Canada.

21
Aug
2017

Scientists unravel role of glutamine synthetase in the spread of cancer

Scientists have discovered an essential mechanism in the spread of cancer. A team led by professor Massimiliano Mazzone (VIB-KU Leuven) and professor Alessandra Castegna (University of Bari) has demonstrated a way to alter the metabolism of macrophages, a particular type of white blood cell often responsible for supporting tumor growth. They found that reducing the glutamine levels of these macrophages changes their behavior: instead of supporting cancer, the macrophages change back into ‘good’ cells and fight the disease. These groundbreaking findings potentially offer new strategies for immunotherapy. The conclusions of the study are published in the leading scientific journal Cell Reports.

17
Aug
2017

Ablynx will announce its 2017 half year results with webcast on 24 august 2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will report its 2017 half year financial results and year-to-date business update on Thursday 24 August 2017 at 7.00 am CET.

17
Aug
2017

argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Thursday, August 24, 2017 at 3:00 p.m. CEST (9:00 a.m. EDT) to discuss financial results for the first half of 2017 and to provide a second quarter business update.

21
Aug
2017

Mithra Announces First Subject Completes Estelle® Phase III Study

Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that the first European study subject has successfully completed 13 cycles of Estelle® and the end of study physician visit in the E4 Freedom Phase III study program. Estelle® is Mithra’s combined oral contraceptive (COC) candidate, composed of 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP), and is currently being tested in two Phase III trials in Europe/Russia and in the US/Canada.

21
Aug
2017

Scientists unravel role of glutamine synthetase in the spread of cancer

Scientists have discovered an essential mechanism in the spread of cancer. A team led by professor Massimiliano Mazzone (VIB-KU Leuven) and professor Alessandra Castegna (University of Bari) has demonstrated a way to alter the metabolism of macrophages, a particular type of white blood cell often responsible for supporting tumor growth. They found that reducing the glutamine levels of these macrophages changes their behavior: instead of supporting cancer, the macrophages change back into ‘good’ cells and fight the disease. These groundbreaking findings potentially offer new strategies for immunotherapy. The conclusions of the study are published in the leading scientific journal Cell Reports.

17
Aug
2017

Ablynx will announce its 2017 half year results with webcast on 24 august 2017

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will report its 2017 half year financial results and year-to-date business update on Thursday 24 August 2017 at 7.00 am CET.

17
Aug
2017

argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Thursday, August 24, 2017 at 3:00 p.m. CEST (9:00 a.m. EDT) to discuss financial results for the first half of 2017 and to provide a second quarter business update.

Z Life Sciences

A look behind the scenes of the vibrant life sciences sector in Flanders, Belgium in 11 episodes.

1

VIB

VIB is a life sciences research institute based in Flanders. With more than 1470 scientists from over 60 countries, they perform basic research into the molecular foundations of life and they translate this research into pharmaceutical, agricultural and industrial applications.

2

imec

imec performs world-leading research in nano-electronics and creates groundbreaking innovation in application domains such as healthcare, smart cities and mobility, logistics and manufacturing, and energy. The combination of their widely acclaimed leadership in microchip technology and profound software and ICT expertise is what makes imec unique.

3

Bio Base Europe Pilot Plant

Bio Base Europe Pilot Plant is an independent, state-of-the-art facility that operates from a laboratory level to a multi-ton scale. Bio Base Europe Pilot Plant provides process development, scale-up and custom manufacturing of biobased products and processes. 

 

E-letter archive

UNDER CONSTRUCTION: here you will be able to consult the archive of our quarterly e-letter.

Interested in a regular update of the Life Sciences and biotech sector in Flanders?